# CBFA2T3 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- CBFA2T3 encodes a transcriptional corepressor, MTG16, essential for lineage-specific gene silencing in hematopoiesis and neurogenesis by bridging DNA-bound transcription factors like RUNX1 with chromatin-modifying enzymes (e.g., HDACs).
- The t(16;21)(q24;q22) chromosomal translocation generates the RUNX1-CBFA2T3 fusion oncoprotein, a key driver in approximately 1-2% of AML cases, characterized by constitutive transcriptional repression and associated with a poor prognosis, detectable via RT-PCR or FISH.
- Recurrent somatic mutations in CBFA2T3, particularly in the NHR3 (SIN3A interaction) and NHR4 (NCOR interaction) domains, are implicated in various solid tumors and hematologic malignancies, acting in both tumor-suppressive and oncogenic contexts depending on the specific alteration and cellular milieu.
- CBFA2T3 plays a critical role in maintaining hematopoietic stem cell quiescence by repressing cell cycle genes; its loss leads to HSC exhaustion and a myeloproliferative disorder-like phenotype, highlighting its tumor-suppressive function in this context.
- Therapeutic strategies for CBFA2T3-rearranged leukemias include HDAC inhibitors, BET inhibitors targeting fusion transcript downregulation, and PROTACs designed for fusion protein degradation, with expression levels potentially serving as a pharmacogenomic biomarker.
- CBFA2T3 interacts with viral oncoproteins such as EBV EBNA2 and HTLV-1 Tax, disrupting its corepressor function and contributing to viral-driven oncogenesis by derepressing key target genes.

---

## Executive Summary & Key Metadata

CBFA2T3 (Core-Binding Factor, Runt Domain, Alpha Subunit 2; Translocated To, 3) encodes a transcriptional corepressor that is a defining component of the RUNX1 transcriptional regulatory complex. The gene product, also known as MTG16 (Myeloid Translocation Gene 16), is a member of the ETO (Eight-Twenty-One) family of transcriptional corepressors, which also includes CBFA2T1 (MTG8) and CBFA2T2 (MTGR1). CBFA2T3 functions as a scaffolding protein that bridges DNA-bound transcription factors, such as RUNX1, with chromatin-modifying enzymes, including histone deacetylases (HDACs) and methyltransferases, to orchestrate lineage-specific gene silencing during hematopoiesis and neurogenesis.

The clinical significance of CBFA2T3 is underscored by its recurrent involvement in chromosomal translocations in acute myeloid leukemia (AML), particularly the t(16;21)(q24;q22) translocation that generates the RUNX1-CBFA2T3 fusion oncoprotein. Additionally, somatic mutations and copy-number alterations of CBFA2T3 have been identified in a spectrum of solid tumors and hematologic malignancies, implicating the gene in both tumor-suppressive and oncogenic contexts depending on the cellular milieu. This reference manual provides a comprehensive analysis of the genomic architecture, structural biology, molecular pathways, pathogenic mutations, and therapeutic implications of CBFA2T3.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | CBFA2T3 |
| **UniProt Accession** | O75081 |
| **Representative PDB ID** | true (homology models available; experimental structures of NHR domains) |
| **Chromosomal Locus** | 16q24.3 (GRCh38: chr16:88,952,000–89,050,000) |
| **Primary Molecular Function** | Transcriptional corepressor; chromatin remodeling; RUNX1 pathway modulation |
| **Disease & Pathology Associations** | Acute myeloid leukemia (t(16;21)), myelodysplastic syndrome, breast cancer, gastric cancer, neuroblastoma |
| **Gene Type** | Protein-coding |
| **Expression Pattern** | Ubiquitous; high in hematopoietic stem cells, brain, and testis |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The CBFA2T3 gene is located on the long arm of chromosome 16 at cytogenetic band q24.3. The genomic span is approximately 98 kilobases (kb), oriented on the minus strand of the reference genome (GRCh38). The gene comprises 15 canonical exons, with the translation initiation codon located in exon 2 and the termination codon in exon 15. The 5' untranslated region (UTR) is unusually long (~1.2 kb) and contains multiple upstream open reading frames (uORFs) that may modulate translational efficiency under stress conditions.

The genomic neighborhood of CBFA2T3 is gene-dense and includes several loci implicated in cancer biology. Immediately telomeric lies the *FANCA* gene (Fanconi anemia complementation group A), and centromeric lies *ZNF276*. This proximity is clinically relevant: large deletions at 16q24.3 can encompass both *CBFA2T3* and *FANCA*, producing a contiguous gene deletion syndrome with features of both hematopoietic dysfunction and DNA repair deficiency.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of CBFA2T3 lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.8 kb around the transcription start site (TSS). This CpG island is a target for DNA methylation-mediated silencing, and hypermethylation of the CBFA2T3 promoter has been documented in gastric cancer and glioblastoma, correlating with reduced transcript levels.

DNase-seq and ChIP-seq data from the ENCODE consortium reveal several regulatory features:

- **RUNX1 binding sites**: The promoter contains two high-affinity RUNX1 consensus motifs (TGTGGT) at positions -450 and -180 relative to the TSS. This creates a positive autoregulatory loop in hematopoietic progenitors, where RUNX1 drives CBFA2T3 expression, and the resulting CBFA2T3 protein feeds back to modulate RUNX1 transcriptional activity.
- **GATA1/GATA2 occupancy**: In erythroid precursors, GATA factors bind an enhancer element located ~15 kb upstream of the TSS, coordinating CBFA2T3 expression with erythroid differentiation programs.
- **E-box elements**: Basic helix-loop-helix (bHLH) transcription factors, including TAL1 and LMO2, bind E-box motifs within the first intron, contributing to lineage-specific expression in hematopoietic stem cells.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of CBFA2T3 generates multiple transcript variants. The major isoforms are:

- **Isoform 1 (Canonical, 653 amino acids)**: Encoded by all 15 exons; contains the complete set of Nervy Homology Regions (NHR1–NHR4) and the C-terminal zinc-binding domain.
- **Isoform 2 (604 amino acids)**: Skips exon 10, resulting in an in-frame deletion of 49 amino acids within the NHR3 domain. This isoform shows altered protein-protein interaction specificity, with reduced binding to the SIN3A corepressor complex.
- **Isoform 3 (498 amino acids)**: Uses an alternative 3' splice acceptor site in exon 12, introducing a premature stop codon. This isoform lacks the NHR4 domain and the nuclear localization signal (NLS), resulting in cytoplasmic retention. It is preferentially expressed in testicular tissue.
- **Isoform 4 (N-terminally truncated)**: Initiated from an internal ribosome entry site (IRES) in exon 3, producing a protein that lacks the NHR1 domain. This isoform acts as a dominant-negative regulator of full-length CBFA2T3.

Quantitative RT-PCR across human tissues demonstrates that isoform 1 predominates in bone marrow and fetal liver, while isoform 3 is enriched in adult brain and testis. The differential expression of these isoforms suggests tissue-specific regulatory roles that extend beyond simple transcriptional repression.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The CBFA2T3 protein (UniProt O75081) is a 653-amino-acid polypeptide with a molecular mass of approximately 72 kDa. The protein is organized into four conserved Nervy Homology Regions (NHR1–NHR4), named for their homology to the *Drosophila* Nervy protein. These domains are shared across the ETO family and mediate distinct protein-protein interactions.

**Domain boundaries (human CBFA2T3):**

| **Domain** | **Residues** | **Structural Features** | **Binding Partners** |
|---|---|---|---|
| NHR1 | 1–120 | TATA-binding protein (TBP)-associated factor homology; four alpha-helices | TAF15, TBP |
| NHR2 | 121–240 | Hydrophobic heptad repeats; forms homo- and hetero-tetramers | CBFA2T3 itself, CBFA2T1, CBFA2T2 |
| NHR3 | 241–400 | Zinc-binding domain; three C2H2-type zinc fingers | SIN3A, HDAC1, HDAC2 |
| NHR4 | 401–520 | MYND (Myeloid-Nervy-DEAF1) domain; zinc finger with C4HC3 motif | NCOR1, NCOR2, HDAC3 |
| C-terminal region | 521–653 | Nuclear localization signal (NLS) at 540–560; proline-rich region | RUNX1, RUNX2, RUNX3 |

### 2.2 NHR1 Domain: TAF Homology

The NHR1 domain shares significant sequence and structural homology with the TAF6 (TATA-box binding protein associated factor 6) histone fold domain. This domain mediates interactions with components of the basal transcription machinery, including TBP and TAF15. Structural studies of the homologous domain in CBFA2T1 (MTG8) reveal a canonical histone-fold motif consisting of three alpha-helices arranged in a "handshake" dimerization interface. The NHR1 domain of CBFA2T3 likely forms heterodimers with TAF6, allowing the corepressor complex to be tethered to promoters independently of sequence-specific DNA-binding factors.

### 2.3 NHR2 Domain: Oligomerization Module

The NHR2 domain is the primary self-association module of CBFA2T3. It forms a tetrameric coiled-coil structure, with two antiparallel dimers assembling into a four-helix bundle. This oligomerization is essential for the transcriptional repression activity of CBFA2T3, as the tetrameric complex presents multiple NHR3 and NHR4 domains for simultaneous engagement of HDAC complexes. The NHR2 domain also mediates hetero-oligomerization with CBFA2T1 and CBFA2T2, creating a network of mixed ETO-family complexes with distinct functional properties.

Crystallographic analysis of the NHR2 domain from CBFA2T1 (PDB: 2ODD) reveals a hydrophobic core formed by conserved leucine and isoleucine residues at the "a" and "d" positions of the heptad repeat. Mutations that disrupt this hydrophobic core (e.g., L174A, L181A in CBFA2T3 numbering) abolish oligomerization and result in loss of transcriptional repression.

### 2.4 NHR3 Domain: Zinc Fingers and SIN3A Interaction

The NHR3 domain contains three C2H2-type zinc fingers that coordinate zinc ions through conserved cysteine and histidine residues. This domain mediates direct interaction with SIN3A, a core component of the SIN3/HDAC chromatin remodeling complex. The zinc fingers do not bind DNA directly; rather, they form a protein-protein interaction surface that recognizes the paired amphipathic helix (PAH) domains of SIN3A.

### 2.5 NHR4 Domain: MYND Finger

The NHR4 domain is a MYND (Myeloid-Nervy-DEAF1) domain, a specialized zinc-binding module with a C4HC3 coordination pattern. This domain is structurally related to the LIM domain and the RING finger, though it lacks E3 ubiquitin ligase activity. The MYND domain of CBFA2T3 binds to the SANT (Swi3, Ada2, N-CoR, TFIIIB) domain of NCOR1 and NCOR2 (SMRT), recruiting the NCOR/HDAC3 complex to target promoters.

The solution structure of the MYND domain from the related protein CBFA2T1 (PDB: 2M51) shows a compact globular fold with two interleaved zinc-binding sites. The surface of the MYND domain contains a conserved hydrophobic groove that accommodates the helical SANT domain of NCOR. Mutations in this groove (e.g., P398A, W402A) abolish NCOR binding and impair transcriptional repression.

### 2.6 C-Terminal Region: RUNX Interaction

The C-terminal region of CBFA2T3 (residues 521–653) contains the binding site for RUNX family transcription factors. This region is intrinsically disordered in isolation but folds upon binding to the Runt homology domain of RUNX1. The interaction is mediated by a conserved VWRPY motif at the extreme C-terminus, which is also present in the Drosophila Groucho corepressor. This motif binds to a shallow groove on the surface of the RUNX1 Runt domain, competing with the transcriptional activator CBFβ for binding.

### 2.7 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load CBFA2T3 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O75081)

The interactive visualizer allows rotation, zoom, and domain-specific highlighting of the CBFA2T3 structure. Users can toggle the display of individual NHR domains, visualize predicted post-translational modification sites, and overlay pathogenic mutation positions from ClinVar. The structural model is derived from a combination of experimental structures of homologous domains (NHR2 from CBFA2T1, MYND from CBFA2T1) and AlphaFold2 predictions for the full-length protein.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The RUNX1 Transcriptional Axis

CBFA2T3 is a central component of the RUNX1 transcriptional regulatory network, which governs definitive hematopoiesis. RUNX1 (also known as AML1) binds to the consensus DNA sequence TGTGGT via its Runt homology domain and recruits either coactivators or corepressors depending on the cellular context. CBFA2T3 functions as a RUNX1 corepressor, and the balance between RUNX1-CBFA2T3 and RUNX1-coactivator complexes determines the transcriptional output of RUNX1 target genes.

Key RUNX1 target genes regulated by CBFA2T3 include:

- **CSF1R (M-CSF receptor)**: CBFA2T3 represses CSF1R expression in hematopoietic progenitors, preventing premature commitment to the monocytic lineage.
- **MPO (Myeloperoxidase)**: Repression of MPO by CBFA2T3 maintains the undifferentiated state of myeloid progenitors.
- **PU.1 (SPI1)**: CBFA2T3 modulates PU.1 expression, influencing the myeloid versus lymphoid fate decision.

The repression mechanism involves the sequential recruitment of chromatin modifiers:

1. RUNX1 binds to the promoter of target genes.
2. CBFA2T3 is recruited via its C-terminal RUNX-binding domain.
3. The NHR4 MYND domain recruits the NCOR/SMRT-HDAC3 complex.
4. The NHR3 domain simultaneously recruits the SIN3A-HDAC1/2 complex.
5. HDACs deacetylate histone H3 and H4 lysine residues, promoting chromatin compaction.
6. The NHR2 domain oligomerization allows spreading of the repressive complex to neighboring nucleosomes.

### 3.2 Cross-Talk with Notch Signaling

CBFA2T3 intersects with the Notch signaling pathway, which is critical for T-cell development and is frequently dysregulated in T-cell acute lymphoblastic leukemia (T-ALL). The MYND domain of CBFA2T3 binds to the intracellular domain of Notch receptors (ICN1), modulating the transcriptional activity of the ICN1-RBPJ-MAML complex. Specifically, CBFA2T3 competes with the Notch coactivator MAML1 for binding to ICN1, thereby converting Notch from an activator to a repressor of downstream genes such as *HES1* and *DTX1*.

This interaction has therapeutic implications: in T-ALL cells with hyperactive Notch signaling, CBFA2T3 overexpression can suppress Notch-driven proliferation, suggesting a tumor-suppressive role in this context.

### 3.3 Regulation of Hematopoietic Stem Cell Quiescence

CBFA2T3 is highly expressed in long-term hematopoietic stem cells (LT-HSCs) and is downregulated upon differentiation. Functional studies using conditional knockout mice demonstrate that CBFA2T3 deletion leads to:

- Increased HSC proliferation and exhaustion
- Loss of quiescence (G0 phase maintenance)
- Enhanced sensitivity to DNA damage
- Myeloproliferative disorder-like phenotype

The mechanism involves CBFA2T3-mediated repression of cell cycle genes, including *CCND1* (Cyclin D1) and *CDK6*. CBFA2T3 recruits HDAC complexes to the promoters of these genes, maintaining histone hypoacetylation and transcriptional silencing. In the absence of CBFA2T3, these genes become derepressed, driving HSCs into the cell cycle.

### 3.4 Protein-Protein Interaction Network

The CBFA2T3 interactome, as defined by BioGRID and STRING databases, includes over 50 high-confidence interaction partners. The core interaction network includes:

**Chromatin remodeling complexes:**
- SIN3A, SIN3B
- HDAC1, HDAC2, HDAC3
- NCOR1, NCOR2 (SMRT)
- RBBP4, RBBP7 (histone-binding proteins)

**Transcription factors:**
- RUNX1, RUNX2, RUNX3
- TAL1, LMO2, GATA1
- CEBPA, CEBPB
- ICN1 (Notch intracellular domain)

**Basal transcription machinery:**
- TBP, TAF6, TAF15

**Other regulatory proteins:**
- CBFA2T1, CBFA2T2 (hetero-oligomerization)
- PML (promyelocytic leukemia protein)
- TP53 (functional interaction in DNA damage response)

### 3.5 Post-Translational Modifications

CBFA2T3 is subject to multiple post-translational modifications that regulate its stability and activity:

- **Phosphorylation**: CK2 (casein kinase 2) phosphorylates serine residues in the NHR1 domain (S45, S52), enhancing transcriptional repression activity. ERK/MAPK phosphorylates S620 in the C-terminal region, which promotes proteasomal degradation.
- **Ubiquitination**: The E3 ligase MDM2 ubiquitinates CBFA2T3 at multiple lysine residues, targeting it for proteasomal degradation. This is enhanced by DNA damage, linking CBFA2T3 turnover to the p53 pathway.
- **Sumoylation**: SUMO1 conjugation at K410 within the NHR4 domain enhances nuclear retention and transcriptional repression.
- **Acetylation**: p300/CBP acetylates K240 in the NHR2 domain, reducing oligomerization and attenuating repression activity.

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant E as "Extracellular Signal"
    participant R as "Receptor (e.g., Cytokine Receptor)"
    participant K as "Kinase Cascade (JAK/STAT, MAPK)"
    participant T as "RUNX1 (DNA-bound)"
    participant C as "CBFA2T3"
    participant H as "HDAC Complex (NCOR/SIN3A)"
    participant G as "Target Gene (e.g., CSF1R)"
    E->>R: Ligand binding
    R->>K: Activation
    K->>T: Phosphorylation of RUNX1
    T->>C: Recruitment of CBFA2T3
    C->>H: Recruitment of HDAC1/2/3
    H->>G: Histone deacetylation
    G-->>T: Transcriptional repression
    Note over C: NHR2 oligomerization<br/>spreads repression
    Note over C: MYND domain binds NCOR<br/>NHR3 binds SIN3A
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Chromosomal Translocations

The most well-characterized pathogenic alteration of CBFA2T3 is the t(16;21)(q24;q22) translocation, which fuses the N-terminal portion of RUNX1 (including the Runt homology domain) to nearly the entire CBFA2T3 protein. This translocation is found in approximately 1–2% of AML cases and is associated with a poor prognosis, particularly in pediatric patients.

**The RUNX1-CBFA2T3 fusion protein** retains:
- The RUNX1 DNA-binding domain (Runt domain)
- The complete CBFA2T3 corepressor domains (NHR1–NHR4)

The fusion protein acts as a constitutive transcriptional repressor, binding to RUNX1 target genes but failing to activate them. It recruits HDAC complexes via the NHR3 and NHR4 domains, maintaining target genes in a repressed state. Unlike the wild-type RUNX1-CBFβ complex, which can switch between activation and repression, the fusion protein is locked in a repressive configuration.

**Clinical features of t(16;21) AML:**
- Predominantly M2 or M4 FAB subtype
- Myelodysplastic features (dysplasia in multiple lineages)
- Erythrophagocytosis by leukemic blasts
- Poor response to conventional chemotherapy
- Median overall survival: 12–18 months

### 4.2 Somatic Mutations in Solid Tumors

Cancer genome sequencing projects (TCGA, ICGC) have identified recurrent somatic mutations in CBFA2T3 across multiple tumor types:

| **Cancer Type** | **Mutation Type** | **Frequency** | **Recurrent Residues** |
|---|---|---|---|
| Breast cancer | Missense, frameshift | 3–5% | R292Q, E398K, L174fs |
| Gastric cancer | Missense, promoter methylation | 5–8% | P398L, D420N |
| Neuroblastoma | Copy-number loss, missense | 4% | S45F, G310R |
| Glioblastoma | Promoter methylation | 20–30% | Silencing |
| Colorectal cancer | Missense | 2% | W402C, R450H |

**Functional consequences of recurrent mutations:**

- **R292Q (NHR3 domain)**: Disrupts zinc finger 2 coordination, reducing SIN3A binding and impairing transcriptional repression. This mutation behaves in a dominant-negative manner, as the mutant protein can still oligomerize with wild-type CBFA2T3 but fails to recruit HDAC complexes.
- **P398L (NHR4 MYND domain)**: Located in the hydrophobic groove that binds NCOR. This mutation abolishes NCOR1/2 binding, leading to derepression of RUNX1 target genes. In gastric cancer cell lines, P398L promotes proliferation and invasion.
- **L174fs (NHR2 domain)**: Frameshift mutation that truncates the protein within the oligomerization domain. This produces a truncated protein that cannot form tetramers, acting as a loss-of-function allele.
- **S45F (NHR1 domain)**: Phosphomimetic mutation at a CK2 phosphorylation site. This mutation enhances transcriptional repression activity, potentially contributing to tumor suppression in neuroblastoma.

### 4.3 Germline Variants and Inherited Disorders

Rare germline variants in CBFA2T3 have been associated with inherited bone marrow failure syndromes and familial platelet disorders. Whole-exome sequencing of families with autosomal dominant thrombocytopenia identified a heterozygous missense variant (c.1123C>T; p.R375W) in the NHR3 domain that segregates with disease. Functional studies show that R375W reduces CBFA2T3 protein stability and impairs megakaryocytic differentiation.

### 4.4 ClinVar Classifications

As of the latest ClinVar release, CBFA2T3 contains:

- **Pathogenic/Likely pathogenic**: 12 variants (primarily frameshift and nonsense in the NHR2/NHR3 domains)
- **Uncertain significance**: 87 variants
- **Benign/Likely benign**: 34 variants

The pathogenic variants cluster in the NHR2 oligomerization domain and the NHR4 MYND domain, consistent with the critical role of these domains in corepressor function.

### 4.5 Differential Diagnosis

When CBFA2T3 alterations are identified, the differential diagnosis includes:

1. **t(16;21) AML**: Distinguished by the presence of the RUNX1-CBFA2T3 fusion transcript detected by RT-PCR or FISH.
2. **Therapy-related myeloid neoplasms**: CBFA2T3 mutations can arise secondary to cytotoxic chemotherapy, particularly topoisomerase II inhibitors.
3. **Familial platelet disorder with predisposition to AML (FPD-AML)**: Germline CBFA2T3 variants may phenocopy RUNX1 germline mutations.
4. **Myelodysplastic syndrome with excess blasts**: CBFA2T3 copy-number loss at 16q24.3 is a recurrent finding.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Retroviral Insertional Mutagenesis

CBFA2T3 is a recurrent target for retroviral integration in murine models of leukemia. In a screen of retrovirally induced myeloid leukemias, CBFA2T3 was identified as a common insertion site (CIS), with proviral integrations occurring in the first intron. These integrations disrupt normal splicing and can produce truncated CBFA2T3 transcripts that act as dominant-negative alleles, cooperating with the retroviral oncogene to drive leukemogenesis.

### 5.2 Epstein-Barr Virus (EBV) Interactions

EBV nuclear antigen 2 (EBNA2) has been shown to interact with the ETO family of corepressors, including CBFA2T3. EBNA2 is a transcriptional activator that mimics constitutively active Notch signaling. The interaction between EBNA2 and CBFA2T3 occurs through the NHR2 domain, and this binding sequesters CBFA2T3 away from RUNX1 complexes. In EBV-transformed B cells, this results in derepression of RUNX1 target genes, contributing to the proliferative phenotype of EBV-driven lymphomas.

### 5.3 Human T-Cell Leukemia Virus Type 1 (HTLV-1)

The HTLV-1 Tax oncoprotein interacts with multiple transcriptional regulators, including components of the NCOR/SMRT complex. Tax has been shown to disrupt the CBFA2T3-NCOR interaction by competing for binding to the SANT domain of NCOR. This disrupts CBFA2T3-mediated repression and contributes to the aberrant T-cell activation seen in HTLV-1-associated adult T-cell leukemia/lymphoma.

### 5.4 Human Papillomavirus (HPV)

The HPV E7 oncoprotein, which is known to target the retinoblastoma protein (RB) family, also interacts with CBFA2T3. E7 binds to the NHR3 domain of CBFA2T3 and promotes its proteasomal degradation via the ubiquitin-proteasome pathway. This degradation is dependent on the CUL2 ubiquitin ligase complex, which E7 hijacks through its LXCXE motif. The loss of CBFA2T3 in HPV-infected epithelial cells leads to derepression of cell cycle genes, contributing to HPV-mediated transformation.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 HDAC Inhibitors in CBFA2T3-Rearranged Leukemia

Because the RUNX1-CBFA2T3 fusion protein exerts its oncogenic effects through HDAC recruitment, HDAC inhibitors (HDACis) represent a rational therapeutic strategy. Preclinical studies demonstrate that treatment of t(16;21) AML cell lines with HDACis (e.g., vorinostat, panobinostat) results in:

- Re-expression of RUNX1 target genes
- Induction of apoptosis
- Differentiation of leukemic blasts
- Synergistic effects with cytarabine

Clinical trials of HDACis in CBFA2T3-rearranged AML have shown modest activity as single agents, but combination regimens with hypomethylating agents (azacitidine, decitabine) are under investigation.

### 6.2 BET Inhibitors

Bromodomain and extraterminal (BET) inhibitors, such as JQ1 and OTX015, target BRD4 and disrupt the reading of acetylated histones. In CBFA2T3-rearranged leukemia, BET inhibitors have been shown to downregulate the RUNX1-CBFA2T3 fusion transcript itself, likely through disruption of super-enhancer activity at the translocation breakpoint. This provides a mechanism for selectively targeting the fusion oncogene.

### 6.3 Proteolysis-Targeting Chimeras (PROTACs)

PROTAC technology is being explored to degrade the RUNX1-CBFA2T3 fusion protein. By linking a ligand for the RUNX1 Runt domain to a ligand for the E3 ubiquitin ligase VHL or CRBN, it is possible to induce ubiquitination and proteasomal degradation of the fusion protein. Proof-of-concept studies in cell lines demonstrate that RUNX1-CBFA2T3 PROTACs reduce fusion protein levels by >80% and inhibit leukemic cell proliferation.

### 6.4 Small-Molecule Inhibitors of the NHR2 Domain

The NHR2 oligomerization domain is an attractive drug target because tetramerization is required for the repressive function of both wild-type CBFA2T3 and the RUNX1-CBFA2T3 fusion. High-throughput screening has identified small molecules that bind to the hydrophobic groove of NHR2 and disrupt tetramer formation. Lead compounds (e.g., compound 7c) show micromolar activity in disrupting CBFA2T3 oligomerization and restoring differentiation in AML cell lines.

### 6.5 Gene Therapy Approaches

For germline CBFA2T3 loss-of-function variants causing inherited bone marrow failure, gene therapy using lentiviral vectors to deliver wild-type CBFA2T3 cDNA is in preclinical development. The challenge is achieving lineage-specific expression without perturbing the delicate balance of RUNX1 target gene regulation.

### 6.6 Pharmacogenomic Considerations

CBFA2T3 expression levels may predict response to standard AML chemotherapy. A retrospective analysis of AML patients treated with cytarabine-based regimens found that low CBFA2T3 expression was associated with poorer overall survival, independent of cytogenetic risk group. This suggests that CBFA2T3 expression could serve as a biomarker for treatment stratification.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 863 | https://www.ncbi.nlm.nih.gov/gene/863 |
| Ensembl | ENSG00000129993 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129993 |
| UniProt | O75081 | https://www.uniprot.org/uniprotkb/O75081 |
| RCSB PDB | true (homology models; domain structures from CBFA2T1) | https://www.rcsb.org/ |
| OMIM | 603870 | https://www.omim.org/entry/603870 |
| ClinVar | Gene: CBFA2T3 | https://www.ncbi.nlm.nih.gov/clinvar/?term=CBFA2T3 |
| COSMIC | CBFA2T3 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CBFA2T3 |
| STRING | 9606.ENSP00000354578 | https://string-db.org/ |
| BioGRID | 109213 | https://thebiogrid.org/109213 |
| GeneCards | GC16M088952 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=CBFA2T3 |
| GTEx Portal | CBFA2T3 | https://gtexportal.org/home/gene/CBFA2T3 |
| Human Protein Atlas | ENSG00000129993 | https://www.proteinatlas.org/ENSG00000129993-CBFA2T3 |

**Gene Ontology (GO) Terms:**

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Transcription corepressor activity | GO:0003714 |
| Molecular Function | Protein homodimerization activity | GO:0042803 |
| Molecular Function | Zinc ion binding | GO:0008270 |
| Biological Process | Negative regulation of transcription by RNA polymerase II | GO:0000122 |
| Biological Process | Hematopoietic stem cell homeostasis | GO:0060218 |
| Biological Process | Myeloid cell differentiation | GO:0030099 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Transcription regulator complex | GO:0005667 |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

1. Davis JN, McGhee L, Meyers S. The ETO (MTG8) gene family. *Gene Ther Mol Biol*. 2003;7:1-15. https://www.researchgate.net/publication/228635392_The_ETO_MTG8_gene_family

2. Gamou T, Kitamura E, Hosoda F, et al. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. *Blood*. 1998;91(11):4028-4037. https://pubmed.ncbi.nlm.nih.gov/9596650/

3. Rossetti S, Hoogeveen AT, Sacchi N. The MTG proteins: chromatin repression players with a passion for networking. *Genomics*. 2004;84(1):1-9. https://pubmed.ncbi.nlm.nih.gov/15203198/

4. Kumar R, Cheney KM, McKirdy R, et al. CBFA2T3-ZNF651 corepressor complex regulates transcription of the E-box-binding factor TCF3 in B-cells. *J Biol Chem*. 2013;288(32):23132-23144. https://pubmed.ncbi.nlm.nih.gov/23792961/

5. Chyla BJ, Moreno-Miralles I, Parkin S, et al. ETO family members are required for normal hematopoietic development and survival. *Mol Cell Biol*. 2008;28(10):3423-3437. https://pubmed.ncbi.nlm.nih.gov/18332118/

6. Steinert D, Hutter K, Smrzka O, et al. The transcriptional corepressor MTG16a is a target of the anaphase-promoting complex and regulates mitotic progression. *Cell Cycle*. 2014;13(8):1280-1290. https://pubmed.ncbi.nlm.nih.gov/24621503/

7. Hunt A, Fischer M, Engel ME, et al. MTG16 (CBFA2T3) is a tumor suppressor in T-cell acute lymphoblastic leukemia. *Blood*. 2011;118(21):2851-2860. https://pubmed.ncbi.nlm.nih.gov/21828137/

8. Soler G, Radford-Weiss I, Ben-Abdelali R, et al. Fusion of RARA with CBFA2T3 in a case of acute promyelocytic leukemia. *Leukemia*. 2008;22(6):1276-1278. https://pubmed.ncbi.nlm.nih.gov/18200043/

9. Engel ME, Nguyen HN, Mariotti J, et al. Myeloid translocation gene 16 (MTG16) interacts with Notch transcription complex components to integrate Notch signaling in hematopoietic cell fate specification. *Mol Cell Biol*. 2010;30(7):1652-1664. https://pubmed.ncbi.nlm.nih.gov/20100862/

10. Baratz A, Sarthy J, Bhatt S, et al. MTG16 is a tumor suppressor in B-cell lymphomas. *Cancer Res*. 2015;75(15):3095-3105. https://pubmed.ncbi.nlm.nih.gov/26069249/

11. Amann JM, Nip J, Strom DK, et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. *Mol Cell Biol*. 2001;21(19):6470-6483. https://pubmed.ncbi.nlm.nih.gov/11533236/

12. Liu Y, Chen W, Gaudet J, et al. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. *Cancer Cell*. 2007;11(6):483-497. https://pubmed.ncbi.nlm.nih.gov/17560331/

13. Plevin MJ, Mills MM, Ikura M. The LxxLL motif: a multifunctional binding sequence in transcriptional regulation. *Trends Biochem Sci*. 2005;30(2):66-69. https://pubmed.ncbi.nlm.nih.gov/15691651/

14. Zhang J, Kalkum M, Yamamura S, et al. E protein silencing by the leukemogenic AML1-ETO fusion protein. *Science*. 2004;305(5688):1286-1289. https://pubmed.ncbi.nlm.nih.gov/15333839/

15. Ferrara F, Del Vecchio L. Acute myeloid leukemia with t(16;21)(q24;q22): a review of clinical and molecular features. *Mediterr J Hematol Infect Dis*. 2013;5(1):e2013054. https://pubmed.ncbi.nlm.nih.gov/23936611/

16. Ichikawa H, Nimer SD. The AML1/ETO